**MHRA**
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

**gov.uk/mhra**

# Decision Cover Letter

## Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-101350-PIP01-24

# Scope of the Application

## Active Substance(s)

DECITABINE; Tetrahydrouridine

## Condition(s)

Treatment of sickle cell disease (SCD)

## Pharmaceutical Form(s)

Capsule, hard ; Tablet; Age appropriate oral formulation

## Route(s) of Administration

ORAL USE

## Name / Corporate name of the PIP applicant

Novo Nordisk Limited

## Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Novo Nordisk Limited submitted to the licensing authority on 19/04/2024 15:09 BST an application for a Paediatric Investigation Plan

The procedure started on 13/01/2025 11:29 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

**gov.uk/mhra**

# Final Decision Letter

MHRA-101350-PIP01-24

Of 06/02/2025 15:21 GMT

On the adopted decision for DECITABINE; Tetrahydrouridine (MHRA-101350-PIP01-24) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for DECITABINE; Tetrahydrouridine , Capsule, hard ; Tablet; Age appropriate oral formulation , ORAL USE .

This decision is addressed to Novo Nordisk Limited, 3 City Place, Beehive Ring Rd, Gatwick, UNITED KINGDOM, RH6 0PA

## ANNEX I

### 1. Waiver

### 1.1 Condition:

| |
|---|
| Treatment of sickle cell disease (SCD) The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 6 months of age Pharmaceutical form(s): Capsule, hard Tablet Age appropriate oral formulation Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s). |

### 2. Paediatric Investigation Plan:

### 2.1 Condition(s):

| |
|---|
| Treatment of sickle cell disease (SCD) |

### 2.2 Indication(s) targeted by the PIP:

| |
|---|
| Treatment of sickle cell disease |

### 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

| |
|---|
| The paediatric population from 6 months to less than 18 years of age |

### 2.4 Pharmaceutical Form(s):

| |
|---|
| Capsule, hard Tablet Age appropriate oral formulation |

### 2.5 Studies:

| Study Type | Number of Studies | Study Description |
|---|---|---|
| **Quality Measures** | 1 | Study 1 Development of an age-appropriate oral formulation for use in children from 6 months to less than 12 years of age. |
| **Non-Clinical Studies** | 0 | Not applicable. |
| **Clinical Studies** | 2 | Study 2 (NN7533-4933) Double-blind, randomised, placebo-controlled trial to evaluate pharmacokinetics, safety, and efficacy of decitabine / tetrahydrouridine in adolescents from 12 years to less than 18 years of age (and adults) with sickle cell disease. Study 3 (NN7533-4788) Open-label, uncontrolled trial to evaluate pharmacokinetics, safety and efficacy of decitabine / tetrahydrouridine in children from 6 months to less than 12 years of age with sickle cell disease. |
| **Extrapolation, Modeling & Simulation Studies** | 2 | Study 4 Modelling and simulation study, to evaluate the use of the product in children from 6 months to less than 18 years of age with sickle cell disease. Extrapolation Plan Studies 2, 3 and 4 are part of the extrapolation plan of efficacy data from adults and adolescents to the paediatric population from children from 6 months to less than 18 years of age with sickle cell disease. |
| **Other Studies** | 0 | Not applicable. |
| **Other Measures** | 0 | Not applicable. |

## 3. Follow-up, completion and deferral of a PIP:

| | |
|---|---|
| **Concerns on potential long term safety and efficacy issues in relation to paediatric use:** | No |
| **Date of completion of the paediatric investigation plan:** | 31/01/2033 |
| **Deferral of one or more studies contained in the paediatric investigation plan:** | Yes |